Characteristics associated with clinical response to pomalidomide in hereditary hemorrhagic telangiectasia.

Pomalidomide response according to germline variant (ENG vs ACVRL1) and clinical characteristics — PATH-HHT randomized trial

Secondary analysis of the PATH-HHT randomized trial identifies clinical predictors of pomalidomide response in HHT: higher baseline Epistaxis Severity Score, concomitant antifibrinolytic therapy, and younger age predicted better response. Conversely, carriers of ACVRL1 germline mutations showed a less robust response compared with ENG, SMAD4, or unknown mutation carriers — a novel, clinically important genotype-response correlation. These findings may guide patient selection for pomalidomide therapy in HHT.

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

Identifying a genotype-by-treatment interaction in HHT is a tangible example of precision medicine in hereditary disease: the same approved drug may have differential efficacy depending on the causative germline gene. The attenuated pomalidomide response in ACVRL1 carriers should inform discussions on genotype-stratified therapeutic strategies in HHT.

Clinical impact : 3/3 · Evidence strength : 2/3 · Novelty : 2/2 · Sample size : 1/1 · Journal quality : 1/1 → Total : 9/10